2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3456 Mutations in isocitrate dehydrogenase genes 1 and 2 (IDH1 and IDH2) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): Associations with blast burden, codon distribution, co-mutations and survival

Paloma Resende, MD, Kira Bucci, MD2, Tarcila Santos Datoguia, MD3, Amanda Ennes Inacio Dias dos Santos, MD4, Juliana Dall Agnol Rocha, MD5, André Dias Américo, MD6, Luiz Ferreira Cortes7, Alexandre Eiji Eiji Kayano, MD8, Luana Nobrega, MD9, Frederico Honorato Honorato Jr, MD10, Jade Zezzi Martins do Nascimento, MD11, Carolina Perrone Marques Ferreira, MD12, Elvira Velloso Sr, Dr13, Paulo Vidal Campregher, MD, PhD14, Nelson Hamerschlak Sr, MD PhD15, Fabio Pires S Santos, MD, PhD16
1 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
2 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
3 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
4 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
5 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
6 BP - A Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil
7 Einstein Hospital Israelita, Sao Paulo, Brazil, Genesis Genomics, Sao Paulo, Brazil
8 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
9 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
10 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
11 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
12 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
13 Einstein Hospital Israelita, Sao Paulo, Brazil, Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
14 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil, Genesis Genomics, Sao Paulo, Brazil
15 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil
16 Einstein Hospital Israelita, São Paulo, SP, Brazil, Sao Paulo, Brazil

Background: Mutations in IDH1 and IDH2 are detected in both MDS and AML, but it is currently unknown whether mutated codons, patterns of co-mutations and their impact on prognosis differ between these neoplasms. We evaluated the distribution of mutations in IDH1 and IDH2 across a large public dataset of patients with MDS and AML.

Methods: We analyzed 9 datasets comprising 8,734 patients tested for both IDH1 and IDH2. Only canonical hotspot mutations IDH1-R132 and IDH2-R140/R172 were included. IDH frequency was compared across blast percentages using the Cochran-Armitage test, and the continuous association between blasts and IDH status was modeled using logistic regression and natural cubic splines. Codon distributions were compared using 2,000 bootstrap replicates. Co-occurrence patterns were tested using Fisher’s exact test. Disease-specific co-mutation patterns were evaluated using logistic regression models with an IDH-by-disease interaction term, tested by likelihood-ratio comparison with the corresponding additive model. Overall survival (OS) was evaluated by study-stratified Cox regression models adjusted for age and ELN 2022 in AML and age and IPSS-R in MDS. Multiple testing was controlled using Benjamini-Hochberg FDR. 

Results: IDH mutations were present in 18.1% of patients with AML (95% CI, 17.1-19.2) and 7.3% of those with MDS (95% CI, 6.4-8.2). Within a single registry comprising patients with MDS and secondary AML, frequency of IDH mutations increased with blast percentage, from 4.7% in patients with <5% blasts to 18.4% in AML (P<0.0001). Each 10-percentage point increase in blast count was associated with higher odds of having an IDH mutation (OR, 1.53; 95% CI, 1.35-1.74). The association was nonlinear, with an increase in the probability of detecting an IDH mutation starting at the threshold of 5% blasts. Although both IDH1 and IDH2 increased in frequency with higher blast burden, the relative increase was steeper for IDH2 than for IDH1 (4.5-fold vs 3.2-fold).

The frequency of IDH mutations varied across ICC 2022 AML subtypes. IDH mutations were more frequent in NPM1-mutated AML (27.7%) and in AML with myelodysplasia-related gene mutations (25.5%) than in AML with myelodysplasia-related cytogenetic abnormalities (9.2%). In contrast, IDH mutations were uncommon in fusion-defined AML entities (0.4-3.6%).

Among IDH-mutated cases, IDH2 R172K was rare in NPM1-mutated AML (0.8%), but more frequent in AML-MR (19.1%) and AML, not otherwise specified (AML-NOS; 30.2%). IDH1 R132C accounted for 24.5% of IDH mutations in AML-MR and 33.3% in TP53-mutated AML, whereas IDH1 R132H was more frequent in NPM1-mutated AML (24.9%) than in AML-MR (2.7%).

Co-mutation patterns varied between MDS and AML. In MDS, IDH1 and IDH2 mutations were strongly associated with SRSF2 (OR, 5.61 and 8.31, respectively). IDH2 was also associated with STAG2 (OR, 5.31) and ASXL1 (OR, 2.70). In AML, both IDH1 and IDH2 were associated with DNMT3A (OR, 2.92 and 2.86, respectively) and NPM1 (OR, 2.51 and 2.04, respectively). Formal interaction testing confirmed that the associations with DNMT3A, SRSF2, STAG2, and ASXL1 differed between AML and MDS.

In survival analyses, IDH mutations were associated with longer overall survival in AML after adjusting for age and ELN 2022 risk categories (HR, 0.87; 95% CI, 0.79-0.96); this effect was mainly seen in patients with IDH2 mutations (HR, 0.82; 95% CI, 0.73-0.92). No association was observed between IDH mutations and survival in patients with MDS after adjusting for age and IPSS-R (HR, 1.03; 95% CI, 0.83-1.29).

Conclusions: The frequency and clinical associations of IDH mutations differed between MDS and AML. IDH mutations became more frequent with an increase in blast count. Our findings suggest three recurring patterns of IDH-mutated myeloid malignancies: (1) NPM1-mutated de novo AML, frequently co-mutated with DNMT3A and enriched for IDH2 R140Q and IDH1 R132H; (2) MDS/AML-MR, associated with SRSF2, STAG2 and ASXL1, and enriched for IDH1 R132C and IDH2 R172K; and (3) AML classified as AML-NOS, enriched for IDH2 R172K. Overall, these findings demonstrate that the biology and clinical significance of IDH mutations vary according to disease context.

Paloma Resende, MD: BeOne - Honoraria; CSL Behring - Honoraria